Associations - BRCA1 mutation

BIOMARKER:

BRCA1 mutation

Entrez ID:

672

Related biomarkers:

‹

›

BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BGB-290 Sensitive: A1 - Approval BeiGene Press Release - 4 days BGB-290 Sensitive : A1 BeiGene Press Release - 4d
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BGB-290 Sensitive: A1 - Approval BeiGene Press Release - 4 days BGB-290 Sensitive : A1 BeiGene Press Release - 4d
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BGB-290 Sensitive: A1 - Approval BeiGene Press Release - 4 days BGB-290 Sensitive : A1 BeiGene Press Release - 4d
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	talazoparib Sensitive: A2 - Guideline ESMO-BC 2021 - 1 week talazoparib Sensitive : A2 ESMO-BC 2021 - 1wk
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	PARP inhibitor Sensitive: B - Late Trials JCO Glob Oncol - 3 weeks PARP inhibitor Sensitive : B JCO Glob Oncol - 3wk
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	niraparib Sensitive: A1 - Approval niraparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval talazoparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: A1 - Approval rucaparib Sensitive : A1
BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab Resistant: A2 - Guideline bevacizumab Resistant : A2
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline vinorelbine tartrate Sensitive : A2

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES